Results 91 to 100 of about 347,631 (311)

Reprogramming tumor immune microenvironment by ultrasound‐responsive nanoplatforms for enhanced cancer immunotherapy

open access: yesBMEMat, EarlyView.
Ultrasound‐responsive nanoplatforms reprogram the tumor immune microenvironment by targeting tumor cells, immune cells, and non‐immune stromal cells to enhance the efficacy of cancer immunotherapy. Abstract Cancer immunotherapy represents a significant advancement in cancer treatment by enhancing the specific recognition and elimination of cancer cells.
Shilong Zhao   +4 more
wiley   +1 more source

DNA sensor cGAS-mediated immune recognition

open access: yesProtein & Cell, 2016
The host takes use of pattern recognition receptors (PRRs) to defend against pathogen invasion or cellular damage. Among microorganism-associated molecular patterns detected by host PRRs, nucleic acids derived from bacteria or viruses are tightly ...
Pengyan Xia   +4 more
doaj   +1 more source

Alpha‐lipoic acid decreases hepatic lipogenesis through adenosine monophosphate‐activated protein kinase (AMPK)‐dependent and AMPK‐independent pathways

open access: yesHepatology, 2008
Fatty liver is common in obese subjects with insulin resistance. Hepatic expression of sterol regulatory element binding protein‐1c (SREBP‐1c), which plays a major role in hepatic steatosis, is regulated by multiple factors, including insulin, adenosine ...
K. Park   +14 more
semanticscholar   +1 more source

A Michaelis‐Arbuzov‐Type Pathway to a Protected 2ʹ‐Deoxy‐2ʹ‐Selenomethyl‐Adenosine‐3ʹ,5ʹ‐Phosphoroselenolate Guanosine Dinucleotide for Use in Modified m7G Cap Synthesis

open access: yesChemistry – A European Journal, EarlyView.
Here we report a synthesis of the dinucleotide 4 for a projected future total synthesis of the m7G cap 1. Highlights of the route include: 1) a 3ʹ‐H‐phosphonate/5ʹ‐selenocyanate Michaelis‐Arbuzov coupling to forge the 3ʹ,5ʹ‐phosphoroselenolate; 2) an Amosova reductive selenomethylation to install the 2ʹ‐SeMe; 3) a solid CPR II 5ʹ‐O‐phosphitylation; and
K. Lawrence E. Hale   +2 more
wiley   +1 more source

A Riboflavin‐Derived Flavinium Salt Mediates Chemoselective Methylation Reactions

open access: yesChemistry – A European Journal, EarlyView.
A two‐component methylation protocol was developed, where the active flavin mediator can be recycled in a single step. Crystallographic data and NMR spectroscopy support the mechanistic proposal, while chemoselective methylation was observed for a broad range of biologically relevant substrates. ABSTRACT Selective methylation is among the most relevant
Tim Langschwager   +3 more
wiley   +1 more source

Thermostable adenosine 5′-monophosphate phosphorylase from Thermococcus kodakarensis forms catalytically active inclusion bodies [PDF]

open access: gold, 2021
Sarah Kamel   +5 more
openalex   +1 more source

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

Semaglutide normalizes increased cardiomyocyte calcium transients in a rat model of high fat diet‐induced obesity

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1386-1397, April 2025.
Sequeira et al. reveal how the glucagon‐like peptide‐1 receptor agonist (GLP‐1‐RA) semaglutide restores cardiomyocyte function in rats subjected to a high‐fat/high‐fructose diet (HFD). Employing fluorescence‐ and patch‐clamp technology in isolated cardiac myocytes, they demonstrate that semaglutide reverses HFD‐induced activation of L‐type calcium ...
Vasco Sequeira   +12 more
wiley   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy